BR100 Increased By (0.88%)
BR30 Increased By (1.28%)
KSE100 Increased By (0.6%)
KSE30 Increased By (0.67%)
BECO 6.06 Increased By ▲ 0.29 (5.03%)
BML 53.20 Increased By ▲ 0.20 (0.38%)
BOP 34.40 Increased By ▲ 0.41 (1.21%)
CNERGY 8.18 Increased By ▲ 0.07 (0.86%)
DCL 12.24 Increased By ▲ 0.04 (0.33%)
FCCL 53.71 Increased By ▲ 0.88 (1.67%)
FCSC 5.15 Increased By ▲ 0.08 (1.58%)
FFL 18.14 Increased By ▲ 0.19 (1.06%)
FNEL 1.30 Increased By ▲ 0.01 (0.78%)
HUMNL 10.90 Increased By ▲ 0.02 (0.18%)
KEL 8.08 Increased By ▲ 0.06 (0.75%)
KOSM 5.41 Decreased By ▼ -0.11 (-1.99%)
MLCF 87.50 Increased By ▲ 0.99 (1.14%)
NBP 187.49 Increased By ▲ 2.33 (1.26%)
PACE 10.70 Increased By ▲ 0.12 (1.13%)
PAEL 39.87 Increased By ▲ 0.45 (1.14%)
PIAHCLA 26.16 Decreased By ▼ -0.06 (-0.23%)
PIBTL 17.46 Increased By ▲ 0.79 (4.74%)
PPL 231.25 Increased By ▲ 3.07 (1.35%)
PRL 34.85 Increased By ▲ 0.17 (0.49%)
PTC 67.01 Increased By ▲ 1.68 (2.57%)
SEARL 90.85 Increased By ▲ 0.72 (0.8%)
SSGC 27.15 Increased By ▲ 0.55 (2.07%)
TELE 8.62 Increased By ▲ 0.34 (4.11%)
THCCL 58.45 Decreased By ▼ -0.05 (-0.09%)
TPLP 8.64 Increased By ▲ 0.42 (5.11%)
TREET 24.66 Increased By ▲ 0.13 (0.53%)
TRG 71.65 Increased By ▲ 1.94 (2.78%)
WAVES 9.99 Increased By ▲ 0.05 (0.5%)
WTL 1.28 No Change ▼ 0.00 (0%)
By

LONDON: Britain has become the first country to approve a COVID-19 vaccine that targets both the original and Omicron variant of the virus.

The the UK medicines regulator (MHRA) approved the so-called bivalent vaccine made by U.S. drug company Moderna as a booster for adults.

The agency’s decision was based on clinical trial data that showed the booster triggered “a strong immune response” against both Omicron (BA.1) and the original 2020 virus, it said.

Southern hemisphere to get first mRNA vaccine facility

The MHRA also cited an exploratory analysis in which the shot was also found to generate a good immune response against the currently dominant Omicron offshoots BA.4 and BA.5.

“The first generation of COVID-19 vaccines being used in the UK continue to provide important protection against the disease and save lives,” MHRA Chief Executive June Raine said in a statement.

“What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve.”

Comments

Comments are closed for this article.